NEUREN PHARMACEUTICALS LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 21.34 AUD | +5.64% |
|
+6.17% | -14.54% |
| 05-09 | Neuren Pharmaceuticals Partner Acadia Pharmaceuticals Posts US DAYBUE Sales of $75.9 Million | MT |
| 04-24 | Neuren Pharmaceuticals Posts AU$243 Million Cash, Short-Term Investments | MT |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 248.4 | 147.3 | 474.9 | 1,001 | 3,178 | 2,725 | - | - |
| Enterprise Value (EV) 1 | 234.6 | 123.1 | 438.1 | 961.2 | 3,178 | 2,436 | 2,327 | 2,213 |
| P/E ratio | -23 x | -14.9 x | -57.1 x | 7,950 x | 20.8 x | 29.8 x | 27.8 x | 14.5 x |
| Yield | - | - | - | - | - | - | - | 3.58% |
| Capitalization / Revenue | 245 x | 153 x | 131 x | 58.8 x | 13.7 x | 17.9 x | 15.8 x | 8.56 x |
| EV / Revenue | 231 x | 128 x | 120 x | 56.4 x | 13.7 x | 16 x | 13.5 x | 6.95 x |
| EV / EBITDA | -21.2 x | -14.4 x | -56.3 x | -606 x | 15.9 x | 20.7 x | 18.3 x | 8.47 x |
| EV / FCF | -20 x | -15.2 x | -43.9 x | 269 x | - | 32.2 x | 18.3 x | 12.3 x |
| FCF Yield | -5% | -6.57% | -2.28% | 0.37% | - | 3.11% | 5.45% | 8.13% |
| Price to Book | - | - | 12.4 x | 24.1 x | - | 8.73 x | 6.72 x | 5.63 x |
| Nbr of stocks (in thousands) | 100,168 | 114,608 | 125,966 | 125,966 | 127,266 | 127,696 | - | - |
| Reference price 2 | 2.480 | 1.285 | 3.770 | 7.950 | 24.97 | 21.34 | 21.34 | 21.34 |
| Announcement Date | 25/02/20 | 23/02/21 | 23/02/22 | 23/02/23 | 29/02/24 | - | - | - |
1AUD in Million2AUD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 1.016 | 0.964 | 3.636 | 17.03 | 231.9 | 152.1 | 172.4 | 318.2 |
| EBITDA 1 | -11.07 | -8.556 | -7.786 | -1.586 | 199.2 | 117.9 | 127.4 | 261.3 |
| EBIT 1 | -10.56 | -8.562 | -7.794 | -1.596 | 199.2 | 121.6 | 120.4 | 181.6 |
| Operating Margin | -1,038.88% | -888.17% | -214.36% | -9.37% | 85.9% | 79.95% | 69.82% | 57.06% |
| Earnings before Tax (EBT) 1 | -10.82 | -9.193 | -7.794 | 0.184 | 205.1 | 139.6 | 149 | 269.3 |
| Net income 1 | -10.82 | -9.193 | -7.794 | 0.184 | 157.1 | 91.34 | 99.33 | 188 |
| Net margin | -1,064.57% | -953.63% | -214.36% | 1.08% | 67.73% | 60.05% | 57.61% | 59.08% |
| EPS 2 | -0.1080 | -0.0860 | -0.0660 | 0.001000 | 1.201 | 0.7153 | 0.7684 | 1.470 |
| Free Cash Flow 1 | -11.73 | -8.084 | -9.98 | 3.58 | - | 75.73 | 126.8 | 179.9 |
| FCF margin | -1,154.63% | -838.59% | -274.48% | 21.02% | - | 49.79% | 73.57% | 56.54% |
| FCF Conversion (EBITDA) | - | - | - | - | - | 64.26% | 99.59% | 68.85% |
| FCF Conversion (Net income) | - | - | - | 1,945.65% | - | 82.91% | 127.69% | 95.7% |
| Dividend per Share 2 | - | - | - | - | - | - | - | 0.7638 |
| Announcement Date | 25/02/20 | 23/02/21 | 23/02/22 | 23/02/23 | 29/02/24 | - | - | - |
1AUD in Million2AUD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2019 S2 | 2020 S1 | 2020 S2 | 2021 S1 | 2021 S2 | 2022 S1 | 2022 S2 | 2023 S1 | 2023 S2 | 2024 S1 | 2024 S2 | 2025 S1 | 2025 S2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 0.733 | 0.554 | 0.41 | - | 3.402 | 0.283 | 16.75 | 64.4 | 169 | 26.95 | 141 | 40 | 127 |
| EBITDA 1 | -3.168 | -4.758 | -3.798 | - | - | - | - | 49.63 | 151.1 | 7.6 | 145.2 | - | - |
| EBIT | -2.931 | -4.761 | -3.801 | - | - | -5.904 | 4.308 | 49.62 | 151.1 | - | - | - | - |
| Operating Margin | -399.86% | -859.39% | -927.07% | - | - | -2,086.22% | 25.72% | 77.05% | 89.4% | - | - | - | - |
| Earnings before Tax (EBT) | -2.931 | -4.761 | -4.432 | - | - | - | - | 49.62 | 155.5 | - | - | - | - |
| Net income | -2.931 | -4.761 | -4.432 | -7.964 | 0.17 | -7.054 | 7.238 | 47.8 | 109.3 | - | - | - | - |
| Net margin | -399.86% | -859.39% | -1,080.98% | - | 5% | -2,492.58% | 43.21% | 74.23% | 64.66% | - | - | - | - |
| EPS 2 | - | - | - | - | - | - | - | 0.3680 | 0.8330 | 0.4700 | 0.6100 | - | - |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 25/02/20 | 25/08/20 | 23/02/21 | 24/08/21 | 23/02/22 | 23/08/22 | 23/02/23 | 27/08/23 | 29/02/24 | - | - | - | - |
1AUD in Million2AUD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - | - | - |
| Net Cash position 1 | 13.8 | 24.2 | 36.8 | 40.2 | - | 289 | 398 | 512 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow 1 | -11.7 | -8.08 | -9.98 | 3.58 | - | 75.7 | 127 | 180 |
| ROE (net income / shareholders' equity) | -78.1% | -48.3% | -24.6% | 0.46% | - | 31.4% | 25.8% | 30.8% |
| ROA (Net income/ Total Assets) | -75.1% | -46.7% | -24% | - | - | 25.4% | 27.4% | 14% |
| Assets 1 | 14.41 | 19.68 | 32.5 | - | - | 359.4 | 362.2 | 1,345 |
| Book Value Per Share 2 | - | - | 0.3000 | 0.3300 | - | 2.450 | 3.180 | 3.790 |
| Cash Flow per Share 2 | -0.1200 | -0.0800 | -0.0800 | - | - | 0.4600 | 0.4500 | 1.060 |
| Capex 1 | - | - | 0.01 | 0.02 | - | 0.36 | 0.36 | - |
| Capex / Sales | - | - | 0.28% | 0.11% | - | 0.24% | 0.21% | - |
| Announcement Date | 25/02/20 | 23/02/21 | 23/02/22 | 23/02/23 | 29/02/24 | - | - | - |
1AUD in Million2AUD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
D+
Sell
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
21.34
AUD
Average target price
26.13
AUD
Spread / Average Target
+22.45%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -14.54% | 1.71B | |
| +31.37% | 588B | |
| -2.60% | 364B | |
| +20.83% | 326B | |
| +5.69% | 285B | |
| +14.83% | 239B | |
| +9.93% | 210B | |
| -6.95% | 200B | |
| +10.77% | 167B | |
| +0.10% | 161B |
- Stock Market
- Equities
- NEU Stock
- Financials Neuren Pharmaceuticals Limited
